Table 4 Pharmacodynamic response for pFAK in pre- and post-dose tumour samples
Subject No. | Visit | pFAK (CU/μg) | Total FAK (CU/μg) | pFAK/FAK | % Change from baseline pFAK | % Change from baseline pFAK/FAK |
|---|---|---|---|---|---|---|
GSK2256098 250 mg BID + trametinib 0.5 mg QD | ||||||
509 | Baseline | 112.070 | 1329.1 | 0.084 | NA | NA |
Day 15 | 13.950 | 585.9 | 0.024 | –87.6 | –71.763 | |
510 | Baseline | 92.400 | 103.3 | 0.895 | NA | NA |
Day 15 | 60.860 | 245.7 | 0.248 | –34.1 | –72.310 | |
202 | Baseline | 189.010 | 680.3 | 0.278 | NA | NA |
Day 22 | 30.960 | 762.1 | 0.041 | –83.6 | –85.378 | |
206 | Baseline | 99.580 | 207.3 | 0.480 | NA | NA |
Day 22 | 50.110 | 59.2 | 0.846 | –49.7 | 76.125 | |
GSK2256098 500 mg BID + trametinib 0.25 mg QD | ||||||
507 | Baseline | 72.750 | 1710.6 | 0.043 | NA | NA |
Day 15 | NA | 1107.3 | NA | NA | NA | |
121 | Baseline | 41.680 | 183.7 | 0.227 | NA | NA |
Day 22 | 25.900 | 214.6 | 0.121 | –37.9 | –46.809 | |
GSK2256098 500 mg BID + trametinib 0.375 mg QD | ||||||
118 | Baseline | 79.470 | 268.6 | 0.296 | NA | NA |
Day 22 | NA | NA | NA | NA | NA | |
GSK2256098 500 mg BID + trametinib 0.5 mg QD | ||||||
200 | Baseline | 15.230 | 12.1 | 1.263 | NA | NA |
Day 22 | 24.600 | 62.0 | 0.397 | −61.5 | –68.586 | |
